Single-dose, Phase 1 Clinical Trial to Evaluate the Safety, and Tolerability of Allogeneic Umbilical Cord-derived Mesenchymal Stem Cell Therapy in Patients With Premature Ovarian Insufficiency
Latest Information Update: 03 Sep 2024
Price :
$35 *
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy-CHABiotech (Primary)
- Indications Primary ovarian insufficiency
- Focus Adverse reactions
- Sponsors CHA Bio & Diostech
- 03 Sep 2024 New trial record